Next Article in Journal
A Novel ARX-Based Approach for the Steady-State Identification Analysis of Industrial Depropanizer Column Datasets
Next Article in Special Issue
Network Analysis Identifies Crosstalk Interactions Governing TGF-β Signaling Dynamics during Endoderm Differentiation of Human Embryonic Stem Cells
Previous Article in Journal
Optimizing the Production of Renewable Aromatics via Crop Oil Catalytic Cracking
Previous Article in Special Issue
Dynamic Modeling of the Human Coagulation Cascade Using Reduced Order Effective Kinetic Models
Article Menu

Export Article

Open AccessReview
Processes 2015, 3(2), 235-256; doi:10.3390/pr3020235

A Quantitative Systems Pharmacology Perspective on Cancer Immunology

1
Department of Basic Pharmaceutical Sciences, West Virginia University, Morgantown, WV 26506, USA
2
Department of Chemical Engineering and Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA
3
Department of Microbiology, Immunology, and Cellular Biology, West Virginia University Morgantown, WV 26506, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Juergen Hahn
Received: 7 December 2014 / Revised: 2 April 2015 / Accepted: 13 April 2015 / Published: 22 April 2015
(This article belongs to the Special Issue Modeling and Analysis of Signal Transduction Networks)
View Full-Text   |   Download PDF [877 KB, uploaded 22 April 2015]   |  

Abstract

The return on investment within the pharmaceutical industry has exhibited an exponential decline over the last several decades. Contemporary analysis suggests that the rate-limiting step associated with the drug discovery and development process is our limited understanding of the disease pathophysiology in humans that is targeted by a drug. Similar to other industries, mechanistic modeling and simulation has been proposed as an enabling quantitative tool to help address this problem. Moreover, immunotherapies are transforming the clinical treatment of cure cancer and are becoming a major segment of the pharmaceutical research and development pipeline. As the clinical benefit of these immunotherapies seems to be limited to subset of the patient population, identifying the specific defect in the complex network of interactions associated with host immunity to a malignancy is a major challenge for expanding the clinical benefit. Understanding the interaction between malignant and immune cells is inherently a systems problem, where an engineering perspective may be helpful. The objective of this manuscript is to summarize this quantitative systems perspective, particularly with respect to developing immunotherapies for the treatment of cancer. View Full-Text
Keywords: pharmaceutical development; cancer immunology; signal transduction; modeling; cross-talk; experimental design; clonal evolution; heterogeneity; quantitative systems pharmacology pharmaceutical development; cancer immunology; signal transduction; modeling; cross-talk; experimental design; clonal evolution; heterogeneity; quantitative systems pharmacology
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Byrne-Hoffman, C.; II, D.J.K. A Quantitative Systems Pharmacology Perspective on Cancer Immunology. Processes 2015, 3, 235-256.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Processes EISSN 2227-9717 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top